We are live on ! Find out more
Boxer Capital

Boxer Capital Portfolio holdings

AUM $2.04B Turnover 20.83%
1-Year Est. Return 108.39%
This Fund
S&P 500
This Quarter Est. Return
+10.82%
1 Year Est. Return
+108.39%
3 Year Est. Return
+261.8%
5 Year Est. Return
+1,135.1%
10 Year Est. Return
–
AUM
$113M
AUM Growth
+$10.6M
Cap. Flow
+$24.6M
Cap. Flow %
21.81%
Top 10 Hldgs %
74.15%
Holding
28
New
6
Increased
4
Reduced
2
Closed
5
Avg Time Held
0.3 years
Top 10 Avg Time Held
0.2 years
Top 20 Avg Time Held
0.3 years

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow Held Since
ONC icon
1
BeOne Medicines
ONC
$45.7B
$14.7M 13.04%
493,630
+76,751
+18% +$2.25M
2016 Q1
1 quarter
BPMC icon
2
DELISTED
Blueprint Medicines
BPMC
$14.3M 12.66%
705,159
– –
2015 Q4
2 quarters
SGEN
3
DELISTED
Seagen
SGEN
$9.4M 8.33%
232,600
-1,000
-0.4% -$38K
2015 Q4
2 quarters
INCY icon
4
Incyte
INCY
$23.6B
$8M 7.09%
100,000
– –
2016 Q1
1 quarter
REGN icon
5
Regeneron Pharmaceuticals
REGN
$95.5B
$6.98M 6.19%
+20,000
New +$7.7M
2016 Q2
0 quarters
ACHC icon
6
Acadia Healthcare
ACHC
$3.2B
$6.52M 5.78%
+200,938
New +$11.8M
2016 Q2
0 quarters
TSRO
7
DELISTED
Tesaro
TSRO
$6.3M 5.59%
+75,000
New +$3.34M
2016 Q2
0 quarters
CLVS
8
DELISTED
Clovis Oncology
CLVS
$6.17M 5.47%
+450,000
New +$6.58M
2016 Q2
0 quarters
NGNE icon
9
Neurogene
NGNE
$475M
$5.81M 5.15%
43,888
+2,887
+7% +$459K
2015 Q4
2 quarters
BMRN icon
10
BioMarin Pharmaceuticals
BMRN
$11.9B
$5.45M 4.83%
70,000
– –
2016 Q1
1 quarter
AVXS
11
DELISTED
AveXis
AVXS
$5.42M 4.81%
142,664
+59,388
+71% +$2.01M
2016 Q1
1 quarter
ARDM
12
DELISTED
Aradigm
ARDM
$4.81M 4.27%
1,101,513
– –
2015 Q4
2 quarters
MRTX
13
DELISTED
Mirati Therapeutics
MRTX
$4.14M 3.67%
757,935
– –
2015 Q4
2 quarters
SNDX icon
14
Syndax Pharmaceuticals
SNDX
$822M
$2.31M 2.05%
234,220
– –
2016 Q1
1 quarter
AKTX icon
15
Akari Therapeutics
AKTX
$15.3M
$1.89M 1.67%
175
– –
2015 Q4
2 quarters
EIGR
16
DELISTED
Eiger BioPharmaceuticals
EIGR
$1.85M 1.64%
3,111
– –
2015 Q4
2 quarters
KURA icon
17
Kura Oncology
KURA
$675M
$1.72M 1.52%
633,692
-11,993
-2% -$37.3K
2015 Q4
2 quarters
CARM icon
18
DELISTED
Carisma Therapeutics
CARM
$1.67M 1.48%
+50,000
New +$1.27M
2016 Q2
0 quarters
ALDX icon
19
Aldeyra Therapeutics
ALDX
$43.6M
$1.66M 1.47%
291,230
+228,084
+361% +$1.27M
2015 Q4
2 quarters
RIGL icon
20
Rigel Pharmaceuticals
RIGL
$776M
$1.56M 1.38%
+70,000
New +$1.74M
2016 Q2
0 quarters
NBRV
21
DELISTED
Nabriva Therapeutics
NBRV
$1.32M 1.17%
707
– –
2015 Q4
2 quarters
NVET
22
DELISTED
Nexvet Biopharma
NVET
$720K 0.64%
154,840
– –
2015 Q4
2 quarters
EPIX icon
23
DELISTED
ESSA Pharma
EPIX
$83K 0.07%
1,405
– –
2015 Q4
2 quarters
QUIT icon
24
Achieve Life Sciences
QUIT
$646M
– –
-40
Closed -$60K –
VTAE
25
DELISTED
Vitae Pharmaceuticals
VTAE
– –
-315,025
Closed -$2.09M –

Similar funds

Boxer Capital's Q2 2016 Portfolio in Review

As of Q2 2016, Boxer Capital held 28 positions worth $113M, up 10% from $102M the previous quarter. Its ten largest holdings account for 74% of the portfolio.

Boxer Capital deployed $24.6M of net new capital in Q2 2016, opening 6 new positions and adding to 4 existing holdings. Its largest new stake was Acadia Healthcare: 200,938 shares worth $6.52M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 89% a quarter earlier.

On the sell side, the largest reduction was Seagen, an estimated $38K trimmed.

  • Boxer Capital's largest Q2 2016 buy was Acadia Healthcare: 200,938 shares worth $6.52M.
  • Boxer Capital added most to BeOne Medicines in Q2 2016, an estimated $2.25M increase.
  • Boxer Capital's biggest Q2 2016 reduction was Seagen, cutting an estimated $38K.
  • Boxer Capital fully exited Celator Pharmaceuticals in Q2 2016, selling an estimated $9.22M.
  • Boxer Capital's ten largest holdings make up 74% of its $113M portfolio in Q2 2016.
  • Boxer Capital opened 6 new positions and closed 5 in Q2 2016.
  • Boxer Capital's portfolio value rose 10% quarter-over-quarter to $113M.

Based on Boxer Capital's 13F filing for Q2 2016, filed 15 Aug 2016.